FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration
- PMID: 20490813
- PMCID: PMC2887939
- DOI: 10.1007/s00401-010-0698-6
FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration
Abstract
Through an international consortium, we have collected 37 tau- and TAR DNA-binding protein 43 (TDP-43)-negative frontotemporal lobar degeneration (FTLD) cases, and present here the first comprehensive analysis of these cases in terms of neuropathology, genetics, demographics and clinical data. 92% (34/37) had fused in sarcoma (FUS) protein pathology, indicating that FTLD-FUS is an important FTLD subtype. This FTLD-FUS collection specifically focussed on aFTLD-U cases, one of three recently defined subtypes of FTLD-FUS. The aFTLD-U subtype of FTLD-FUS is characterised clinically by behavioural variant frontotemporal dementia (bvFTD) and has a particularly young age of onset with a mean of 41 years. Further, this subtype had a high prevalence of psychotic symptoms (36% of cases) and low prevalence of motor symptoms (3% of cases). We did not find FUS mutations in any aFTLD-U case. To date, the only subtype of cases reported to have ubiquitin-positive but tau-, TDP-43- and FUS-negative pathology, termed FTLD-UPS, is the result of charged multivesicular body protein 2B gene (CHMP2B) mutation. We identified three FTLD-UPS cases, which are negative for CHMP2B mutation, suggesting that the full complement of FTLD pathologies is yet to be elucidated.
Similar articles
-
The most common type of FTLD-FUS (aFTLD-U) is associated with a distinct clinical form of frontotemporal dementia but is not related to mutations in the FUS gene.Acta Neuropathol. 2011 Jul;122(1):99-110. doi: 10.1007/s00401-011-0816-0. Epub 2011 Mar 20. Acta Neuropathol. 2011. PMID: 21424531
-
Frequency of ubiquitin and FUS-positive, TDP-43-negative frontotemporal lobar degeneration.J Neurol. 2010 May;257(5):747-53. doi: 10.1007/s00415-009-5404-z. Epub 2009 Nov 28. J Neurol. 2010. PMID: 19946779 Free PMC article.
-
Neuronal cytoplasmic inclusions in tau, TDP-43, and FUS molecular subtypes of frontotemporal lobar degeneration share similar spatial patterns.Folia Neuropathol. 2017;55(3):185-192. doi: 10.5114/fn.2017.70482. Folia Neuropathol. 2017. PMID: 28984110
-
RNA Binding Proteins and the Pathogenesis of Frontotemporal Lobar Degeneration.Annu Rev Pathol. 2019 Jan 24;14:469-495. doi: 10.1146/annurev-pathmechdis-012418-012955. Epub 2018 Oct 24. Annu Rev Pathol. 2019. PMID: 30355151 Free PMC article. Review.
-
Frontotemporal lobar degeneration: diversity of FTLD lesions.Rev Neurol (Paris). 2013 Oct;169(10):786-92. doi: 10.1016/j.neurol.2013.07.015. Epub 2013 Sep 12. Rev Neurol (Paris). 2013. PMID: 24035575 Review.
Cited by
-
Reduced Tau protein expression is associated with frontotemporal degeneration with progranulin mutation.Acta Neuropathol Commun. 2016 Jul 19;4(1):74. doi: 10.1186/s40478-016-0345-0. Acta Neuropathol Commun. 2016. PMID: 27435172 Free PMC article.
-
Knockdown of the Drosophila fused in sarcoma (FUS) homologue causes deficient locomotive behavior and shortening of motoneuron terminal branches.PLoS One. 2012;7(6):e39483. doi: 10.1371/journal.pone.0039483. Epub 2012 Jun 19. PLoS One. 2012. PMID: 22724023 Free PMC article.
-
Advances in understanding the molecular basis of frontotemporal dementia.Nat Rev Neurol. 2012 Aug;8(8):423-34. doi: 10.1038/nrneurol.2012.117. Epub 2012 Jun 26. Nat Rev Neurol. 2012. PMID: 22732773 Free PMC article. Review.
-
The genetics and neuropathology of frontotemporal lobar degeneration.Acta Neuropathol. 2012 Sep;124(3):353-72. doi: 10.1007/s00401-012-1029-x. Epub 2012 Aug 14. Acta Neuropathol. 2012. PMID: 22890575 Free PMC article. Review.
-
Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration.Brain. 2011 Sep;134(Pt 9):2565-81. doi: 10.1093/brain/awr198. Brain. 2011. PMID: 21908872 Free PMC article.
References
-
- Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, Lindholm C, Snowden J, Adamson J, Sadovnick AD, Rollinson S, Cannon A, Dwosh E, Neary D, Melquist S, Richardson A, Dickson D, Berger Z, Eriksen J, Robinson T, Zehr C, Dickey CA, Crook R, McGowan E, Mann D, Boeve B, Feldman H, Hutton M. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature. 2006;442:916–919. doi: 10.1038/nature05016. - DOI - PubMed
-
- Beck J, Rohrer JD, Campbell T, Isaacs A, Morrison KE, Goodall EF, Warrington EK, Stevens J, Revesz T, Holton J, Al Sarraj S, King A, Scahill R, Warren JD, Fox NC, Rossor MN, Collinge J, Mead S. A distinct clinical, neuropsychological and radiological phenotype is associated with progranulin gene mutations in a large UK series. Brain. 2008;131:706–720. doi: 10.1093/brain/awm320. - DOI - PMC - PubMed
-
- Cairns NJ, Grossman M, Arnold SE, Burn DJ, Jaros E, Perry RH, Duyckaerts C, Stankoff B, Pillon B, Skullerud K, Cruz-Sanchez FF, Bigio EH, Mackenzie IR, Gearing M, Juncos JL, Glass JD, Yokoo H, Nakazato Y, Mosaheb S, Thorpe JR, Uryu K, Lee VM, Trojanowski JQ. Clinical and neuropathologic variation in neuronal intermediate filament inclusion disease. Neurology. 2004;63:1376–1384. - PMC - PubMed
-
- Cairns NJ, Neumann M, Bigio EH, Holm IE, Troost D, Hatanpaa KJ, Foong C, White CL, III, Schneider JA, Kretzschmar HA, Carter D, Taylor-Reinwald L, Paulsmeyer K, Strider J, Gitcho M, Goate AM, Morris JC, Mishra M, Kwong LK, Stieber A, Xu Y, Forman MS, Trojanowski JQ, Lee VM, Mackenzie IR. TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol. 2007;171:227–240. doi: 10.2353/ajpath.2007.070182. - DOI - PMC - PubMed
-
- Cairns NJ, Uryu K, Bigio EH, Mackenzie IRA, Gearing M, Duyckaerts C, Yokoo H, Nakazato Y, Jaros E, Perry RH, Arnold SE, Lee VMY, Trojanowski JQ. alpha-Internexin aggregates are abundant in neuronal intermediate filament inclusion disease (NIFID) but rare in other neurodegenerative diseases. Acta Neuropathol. 2004;108:213–223. doi: 10.1007/s00401-004-0882-7. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- 089701/WT_/Wellcome Trust/United Kingdom
- P01 AG017586/AG/NIA NIH HHS/United States
- G0701441/MRC_/Medical Research Council/United Kingdom
- P30 AG012300/AG/NIA NIH HHS/United States
- P01 AG019724/AG/NIA NIH HHS/United States
- P30 AG013854-149003/AG/NIA NIH HHS/United States
- UL1 RR024982/RR/NCRR NIH HHS/United States
- R01 NS065782/NS/NINDS NIH HHS/United States
- MC_U123182015/MRC_/Medical Research Council/United Kingdom
- P30 AG013854/AG/NIA NIH HHS/United States
- P50 AG16574/AG/NIA NIH HHS/United States
- AG10124/AG/NIA NIH HHS/United States
- P30 AG13854/AG/NIA NIH HHS/United States
- NS65782-01 J/NS/NINDS NIH HHS/United States
- G0601846/MRC_/Medical Research Council/United Kingdom
- UL1RR024982/RR/NCRR NIH HHS/United States
- G0801306/MRC_/Medical Research Council/United Kingdom
- AG17546/AG/NIA NIH HHS/United States
- MC_U123160657/MRC_/Medical Research Council/United Kingdom